Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232310 · ClinicalTrials.gov registry record · Phase 2
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00232310 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 150 participants.
The verdict
NCT00232310, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
Interventions
- DRUG CELIVARONE (SSR149744C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232310
The ClinicalTrials.gov registry entry for NCT00232310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CELIVARONE (SSR149744C) is the first listed.
NCT00232310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232310 about?
NCT00232310 is a clinical study titled "Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr". Double blind study to assess versus placebo the efficacy of SSR149744C for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.
What is the current status of trial NCT00232310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-10. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00232310?
The interventions under investigation include: CELIVARONE (SSR149744C) (DRUG).
Who is sponsoring clinical trial NCT00232310?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.